Gallant
CompanyUnited States
Gallant develops 5 assets, the furthest in veterinary (Canine Atopic Dermatitis in canine atopic dermatitis). Mostly cell therapy; based in the United States.
- 5
- Assets
- Furthest stage
- Veterinary
- Raised
- US$22m
- 0
- Trials
- 0
- Signals
Pipeline
5Mesenchymal stromal cells reduce inflammation and improve skin barrier function.
Veterinary, Cell therapy, canine atopic dermatitis
Mesenchymal stromal cells reduce inflammation and support joint health.
Veterinary, Cell therapy, canine osteoarthritis
Mesenchymal stromal cells target inflammation and support kidney health.
Veterinary, Cell therapy, feline chronic kidney disease
2 more assets
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Funding rounds and grants2
- People15
- Similar companies1